Organic & Biomolecular Chemistry
Paper
multidisciplinary fields for the preparation of potential bio-
logically active pyrrolo[1,2-a]quinoxaline derivatives.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
We gratefully acknowledge the financial support of this work
by the National Natural Science Foundation of China (No.
21563025). We also thank Jixing Zhao and Leifang Wu from
the Analysis and Testing Center of Shihezi University for their
help with X-ray single-crystal analysis.
Scheme 5 Plausible reaction mechanism.
addition of 2,6-di-tert-butyl-4-methylphenol (BHT) significantly
inhibited the reaction. All these indicated that the reaction is
likely to proceed via a radical pathway (Scheme 4[a]). When
hydrazine hydrate was replaced with p-toluenesulfonyl hydra-
zine, the iodination of pyrrolo[1,2-a]quinoxaline 1a did not
occur. This fact shows that p-toluenesulfonyl hydrazide is
essential (Scheme 4[b]). In addition, the control reaction of 1a
with I2 in the absence of TsOH only gives 51% yield of 3a. This
result means that p-toluenesulfonic acid has an obvious pro-
motion effect on the iodination. When p-toluenesulfinic acid
was used instead of TsOH to catalyze the iodination, the yield
of 3a was not improved (Scheme 4[c]). This experiment shows
that p-toluenesulfinic acid does not promote the reaction.
Next, we propose a plausible mechanism of iodination on
the basis of our experimental results (Scheme 5). First, the
iodine anion is oxidized into a tert-butoxy radical and elemen-
tal iodine. With the participation of tert-butoxy radicals, a sul-
fonyl radical is generated by the reaction of sulfonyl hydrazide
with TBHP.16 Subsequently, the sulfonyl radical interacts with
TBHP to produce p-toluenesulfonic acid (TsOH). Next, the iodi-
nation of 1a at the C3-position is achieved to form the desired
product 3a under the action of TsOH (route 1). On the other
hand, when indolo[1,2-a]quinoxaline 1q is used as the reac-
tant, the sulfonyl radical reacts with 1q to afford the arylsulfo-
nylated product 3q′ (route 2).17
Notes and references
1 A. Huang and C. Ma, Mini-Rev. Med. Chem., 2013, 13, 607.
2 (a) L. Ronga, M. Del Favero, A. Cohen, C. Soum, P. Le Pape,
S. Savrimoutou, N. Pinaud, C. Mullie, S. Daulouede,
P. Vincendeau, N. Farvacques, P. Agnamey, F. Pagniez,
S. Hutter, N. Azas, P. Sonnet and J. Guillon, Eur. J. Med.
Chem., 2014, 81, 378; (b) A. Jonet, J. Guillon, C. Mullie,
A. Cohen, G. Bentzinger, J. Schneider, N. Taudon,
S. Hutter, N. Azas, S. Moreau, S. Savrimoutou, P. Agnamey,
A. Dassonville-Klimpt and P. Sonnet, Med. Chem., 2018, 14,
293; (c) J. Guillon, A. Cohen, N. M. Gueddouda, R. N. Das,
S. Moreau, L. Ronga, S. Savrimoutou, L. Basmaciyan,
A. Monnier, M. Monget, S. Rubio, T. Garnerin, N. Azas,
J. L. Mergny, C. Mullie and P. Sonnet, J. Enzyme Inhib. Med.
Chem., 2017, 32, 547.
3 H. Xu and L. L. Fan, Eur. J. Med. Chem., 2011, 46, 1919.
4 E. Morelli, S. Gemma, R. Budriesi, G. Campiani,
E. Novellino, C. Fattorusso, B. Catalanotti, S. S. Coccone,
S. Ros, G. Borrelli, V. Kumar, M. Persico, I. Fiorini,
V. Nacci, P. Ioan, A. Chiarini, M. Hamon, A. Cagnotto,
T. Mennini, C. Fracasso, M. Colovic, S. Caccia and
S. Butini, J. Med. Chem., 2009, 52, 3548.
5 (a) J. Guillon, M. Le Borgne, C. Rimbault, S. Moreau,
S. Savrimoutou, N. Pinaud, S. Baratin, M. Marchivie,
S. Roche, A. Bollacke, A. Pecci, L. Alvarez, V. Desplat and
J. Jose, Eur. J. Med. Chem., 2013, 65, 205; (b) V. Desplat,
S. Moreau, A. Gay, S. B. Fabre, D. Thiolat, S. Massip,
G. Macky, F. Godde, D. Mossalayi, C. Jarry and J. Guillon,
J. Enzyme Inhib. Med. Chem., 2010, 25, 204.
6 (a) V. Desplat, M. Vincenzi, R. Lucas, S. Moreau,
S. Savrimoutou, N. Pinaud, J. Lesbordes, E. Peyrilles,
M. Marchivie, S. Routier, P. Sonnet, F. Rossi, L. Ronga and
J. Guillon, Eur. J. Med. Chem., 2016, 113, 214; (b) V. Desplat,
M. Vincenzi, R. Lucas, S. Moreau, S. Savrimoutou, S. Rubio,
N. Pinaud, D. Bigat, E. Enriquez, M. Marchivie, S. Routier,
P. Sonnet, F. Rossi, L. Ronga and J. Guillon,
ChemMedChem, 2017, 12, 940; (c) T. Wang, Y. Tang,
Conclusions
In summary, we have developed a regioselective C3–H iodina-
tion of pyrrolo[1,2-a]quinoxalines. Using TBAI as an iodine
source, pyrrolo[1,2-a]quinoxalines are iodinated at the C3-posi-
tion in the presence of TsNHNH2 as a reducing agent, yielding
3-iodopyrrolo[1,2-a]quinoxaline derivatives. Using I2 as an
iodine source, 3-iodopyrrolo[1,2-a]quinoxalines are also
formed under the action of a catalytic amount of PTSA·H2O.
The two methods represent novel strategies for selective C3–H
iodination and feature excellent regioselectivity, broad sub-
strate scope, gram-scale synthesis, and diverse transformations
of the products. The reaction should gain much attention in
This journal is © The Royal Society of Chemistry 2021
Org. Biomol. Chem., 2021, 19, 5191–5196 | 5195